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The precisemanipulation of growth factor signaling is central to the progress of tissue engineering.Methods
for direct time-resolved activation of signaling pathways through controlled receptor dimerization have
been reported; however, these suffer from the risks associated with gene transfer. Here we present an
alternative gene transfer-free approach in the form of a protein switch featuring pharmacologically
controlled ON-OFF regulation of growth factor activity. The reversible operation of the switch enables
stimulation of target processes within a defined period of time. The protein switch provides ameans for both
studying andmanipulating signaling processes, and is thus believed to be a valuable tool for basic research as
well as tissue engineering and biomedical applications.
C
ontrolled growth factor signaling plays a key role in the advancement of tissue engineering and can provide
an improved insight into growth factor-mediated cellular processes. Existing methods for the direct
activation of growth factor signaling pathways are based on controlled dimerization of the receptor1–3.
Although these methods provide a means for controlling growth factor-mediated pathways in a highly specific
and time-resolved manner, they rely on gene transfer and therefore suffer from the risk of serious side effects4,5.
Here we address this drawback by proposing an alternative, gene transfer-free, approach based on the control of
the growth factor rather than the receptor. The control of growth factors belonging to the cysteine-knot super-
family is of special interest, since these are pivotal in a wide spectrum of cellular processes, such as cell develop-
ment, differentiation, and reprogramming6,7. The cysteine-knot growth factors bind their cognate receptors as
dimers, which brings the receptor subunits into close association and initiates downstream signaling processes8.
We have exploited these properties to construct a generic ‘‘protein switch’’ featuring smallmolecule-inducedON-
OFF regulation of the activity of cysteine-knot growth factors.
Results
The switch consists of a chimeric protein with an engineered monomeric variant of the protein of interest (POI)
fused to the inducible dimerization domain of the bacterial protein gyrase B (GyrB) (Fig. 1). In its default state the
switch is OFF due to its monomeric structure, which prohibits dimerization and thereby activation of the protein
receptor. The switch is turned ON upon the addition of coumermycin. Each coumarine ring of the coumermycin
bind a GyrB, leading to dimerization of the protein and thus the activation of the receptor and downstream
signaling processes. The switch is turned OFF by the administration of novobiocin, upon which the single
coumarine ring of the novobiocin competitively inhibits binding of coumermycin to GyrB, returning the protein
to its monomeric state.
In this study the vascular endothelial growth factor A isoform 121 (VEGF), essential for angiogenesis and
vasculogenesis, was used as an example protein for the characterization of the switch. In order to generate a
monomeric version of VEGF the cysteine residues on positions 51 (C51) and 60 (C60) responsible for the
formation of two antiparallel intermolecular disulfide bonds were substituted with alanine residues (VEGF
(C51-A, C60-A)) using site-specific mutagenesis. The resulting gene was fused to a flexible glycine-serine
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encoding linker (gs-linker) followed by the gene encoding for the N-
terminal domain of GyrB and the sequence for a hexahistidine tag
(His6) (VEGFSWITCH: VEGF (C51-A, C60-A)-gs-linker-GyrB-His6)
(Supplementary Information (SI) Fig. 1a). VEGFSWITCH was pro-
duced as a soluble cytoplasmatic protein in Escherichia coli and puri-
fied by immobilized-metal affinity chromatography (SI Fig 1b). The
non-essential cysteine residue on position 116 is known to form a
third interchain disulfide bridge, but was in this study not mutated
since it is suggested to improve protein stability9. In order to avoid
spontaneous dimerization, the free cysteines were alkylated and the
monomeric fraction of the switch was subsequently isolated using
size exclusion chromatography (SI Fig. 1c).
Inducible dimer- and monomerization of the switch were charac-
terized by size exclusion chromatography. The molecular weight
peak at 50 kDa shown in Fig. 2a confirms the monomeric nature
of the switch (VEGFSWITCH-OFF). The addition of coumermycin
shifts the molecular weight peak to 100 kDa, indicating an inducible
transition to a dimeric state (VEGFSWITCH-ON). By subsequently
adding an excess amount of novobiocin the molecular weight peak
returns to its initial position at 50 kDa, which demonstrates the fully
reversible operation of the switch (Fig. 2a). The binding affinity of the
three VEGFSWITCH variants to the VEGF receptor 2 (VEGFR2) was
examined by fitting the saturation curve y5 xBMAX/(KD1 x) to the
experimentally determined receptor-bound protein fraction (y) ver-
sus the protein concentration (x). The relative binding parameters
BMAX and KD are similar for the three different VEGFSWITCH var-
iants, as seen in Fig. 2b.
In order to examine the bioactivity of the dimeric protein config-
uration (VEGFSWITCH-ON), its ability to stimulate VEGFR2-phos-
phorylation in human umbilical vein endothelial cells (HUVECs)
was compared to that of intact VEGF without the GyrB domain
(VEGF) and intact VEGF fused to GyrB (VEGFGyrB) using
Western blotting (Fig. 3a) with GyrB as a negative control. It can
be seen that VEGFSWITCH-ON is bioactive, albeit at a lower level than
VEGF and VEGFGyrB at equal concentrations. However, by increas-
ing the VEGFSWITCH-ON concentration similar activity levels as for
VEGF and VEGFGyrB were reached (Fig. 3a). In addition, the ability
of VEGFSWITCH-ON to dose-dependently activate downstream pro-
tein expression in HUVECs was confirmed by examining the endo-
genous delta like ligand 4 (DLL4) levels in the cells after stimulation
with VEGFSWITCH-ON at various concentrations (Fig. 3b).
VEGF-governed endothelial cell migration is a complex process
that relies on the coordination between numerous signaling path-
ways10. As this process is a key component in angiogenesis, methods
enabling the study and regulation of endothelial cell migration are
highly valuable for both basic research and tissue engineering. Here
we demonstrate the use of VEGFSWITCH for time-resolved stimu-
lation of three-dimensional migration of HUVECs assembled into
microtissues under in vivo-like conditions. As shown in Fig. 4a, only
background migration of the cells from the microtissue is observed
when the switch is in its default OFF-state, i.e. without any inducer.
The addition of coumermycin turns the switch ON, resulting in
stimulated cell migration (Fig. 4b). Fig. 4c and Fig. 4d show
the microtissues after turning the switch OFF by administrating
Figure 1 | Schematic representation of the protein switch. The protein switch is based on a chimeric protein consisting of an engineered monomeric
variant of the protein of interest (POI) that is fused to the inducible dimerization domain of the bacterial protein gyrase B (GyrB). The switch is OFF in its
default state; the monomeric configuration of the switch prohibits dimerization and thereby activation of the growth factor receptor. The switch is
turned ON upon the addition of coumermycin. Each coumarine ring of the coumermycin binds one GyrB, leading to the dimerization of the growth
factor and subsequently phosphorylation of the receptor and activation of the downstream signaling pathways. The switch is turned OFF by the addition
of an excess novobiocin amount. The coumarine ring of the novobiocin competitively inhibits binding between coumermycin and GyrB whereby the
switch returns to an inactive monomeric state.
www.nature.com/scientificreports
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novobiocin immediately respectively 1 hour after the coumermycin.
The immediate addition of novobiocin prevents any migration,
whereas limited migration is observed in the case where the cells
were stimulated for a time period of 1 hour.
Discussion
We have reported on the construction of a protein switch providing
ON-OFF regulation of the protein activity, which enables stimu-
lation of the target process over a precise period of time. The switch
was realized by engineering a VEGF version, which is inactive in its
default monomeric state and active in its dimeric state. We showed
inducible dimerization and subsequent re-monomerization of the
switch and confirmed bioactivity in the dimerized ON-state by
receptor phosphorylation as well as stimulated downstream protein
expression. ON-OFF regulation was demonstrated by using the
switch for activating and deactivating the three-dimensional migra-
tion of HUVECs in a time-resolved and tunable manner.
Compared to existing methods for time-resolved growth factor
signaling based on controlled receptor dimerization1–3, our switch
has the advantage of being gene transfer-free and thus avoids the
associated side-effects4,5. VEGF variants that bind to their receptor
but fail to activate it are known to function as antagonists11. In
potential in vivo applications we therefore expect excess amounts
of VEGFSWITCH to outcompete endogenous VEGF as it binds to its
receptor in both the monomeric OFF-state and in the induced
dimeric ON-state. The present switch designmay serve as a blueprint
for the construction of a wide range of protein switches using other
dimeric growth factors, primarily those found in the cysteine-knot
superfamily. The precise ON-OFF operation of the switch illustrates
its potential as a tool for elucidating the complex temporal orches-
tration of the signaling pathways underlying endothelial cell migra-
tion, as well as for the guidance of angiogenic processes in tissue
engineering.
Methods
Construction of expression vectors. The vascular endothelial growth factor isoform
121 (VEGF) was amplified from plasmid pBM04312 and the cysteine residues on
amino acid positions 51 and 60 were replaced with alanine residues using site-specific
mutagenesis. The encoding sequence for the N-terminal domain of the bacterial
gyrase subunit B (GyrB) protein and the sequence for a hexahistidine tag (His6) were
amplified from plasmid pWW87313. The two fragments were fused together via a
glycine-serine flexible encoding linker sequence (gs-linker) and cloned into the vector
pWW30114, resulting in the bacterial T7 promoter-based expression vector pLMK550
for the production of VEGFSWITCH (VEGF (C51-A, C60-A)-gs-linker-GyrB-His6)
with the following amino acid sequence:
MAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPS
AVPLMRCGGACNDEGLECVPTEESITMQIMRIKPHQGQHIGEMSFLQHNKCE
CRPKKDRARQEKCDKPRRDIGGGGSGGGGSGGGGSARMSNSYDSSSIKVLK
GLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGHCKEIIVTI
HADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKV
SGGLHGVGVSVVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEK
TGTMVRFWPSLETFTNVTEFEYEILAKRLRELSFLNSGVSIRLRDKRDGKED
HFHYEGHHHHHH.
VEGF, bold and italics; Mutations, bold, italics and underlined; GS-linker,
underlined; GyrB, bold; his6, italics.
The expression vector for a non-mutated version of the fusion protein was cloned
in the same way as pLMK550 except that the site-specific mutagenesis was excluded,
resulting in plasmid pLMK619 for the expression of VEGFGyrB (VEGF-gs-linker-
GyrB-His6). The construction of the VEGF15,16 and the GyrB13 expression vectors has
been described previously. Details regarding protein production and size exclusion
chromatography are given in the Supplementary Information.
Inducible dimerization and monomerization of VEGFSWITCH. The monomeric
structure, inducible dimerization, and reversible monomerization of the switch were
characterized by incubating the protein (40 ng ml21) at room temperature with,
respectively, dimethyl sulfoxide alone (DMSO, Pan Biotech, Aidenbach, Germany,
cat. no. P60-36720100) (0.23% v/v) for 60 min, 1 ng ml21 coumermycin (Sigma-
Aldrich, Steinheim, Germany, cat. no. C9270) dissolved in DMSO, or with 1 ng ml21
coumermycin for 30 min followed by 30 min with 1.8 mg ml21 novobiocin (Carl
Roth, Karlsruhe, Germany, cat. no. C247.3) added. The protein molecular weights
resulting from the different incubation conditions were subsequently analyzed by size
exclusion chromatography according to the above described protocol. The VEGF
concentrations in the fractions eluted between 62.5 ml and 92.5 ml, corresponding to
molecular weights ranging from 14 kDa to 200 kDa, were quantified via VEGF
ELISA (Peprotech, Hamburg, Germanz, cat. no. 900-K10). The coumermycin and
novobiocin concentrations given above were used in all subsequent experiments.
Receptor-ligand binding affinity. The receptor-ligand binding affinity experiment
was performed by ELISA. VEGFR2 (Life Technologies, Karlsruhe, Germany, cat. no.
PV3660) was diluted in Tris-buffered saline (TBS; 50 mM Tris pH 7.8 and 150 mM
NaCl) to a final concentration of 4 ngml21 and 100 ml were added to eachwell of a 96-
well ELISA plate (Corning, Lowell, MA, cat. no. 3590) followed by overnight
incubation at room temperature. The plate was washed three times with TBS
containing 0.05% (v/v) Tween-20; the same procedure was used for all subsequent
washing steps. Non-specific binding sites were blocked by incubation for 2 h with
300 ml blocking buffer (TBS containing 5% (w/v) bovine serum albumin (BSA, Fluka,
Buchs, Switzerland, cat. no. 05479)) after which the plate was washed. The various
VEGFSWITCH versions were diluted in TBS containing 5% BSA of which 100 ml were
added to eachwell. The plate was washed after 2 h of incubation at room temperature.
The receptor-bound proteins were detected according to the manufacturer’s protocol
using the VEGF detection antibody and the avidin-HRP conjugate antibody from the
VEGF ELISA. After washing, the ELISAwas developed by adding 100 ml per well of 2,
29-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) reagent (0.03%, w/v,
Sigma-Aldrich, cat. no. A1888), and H2O2 (0.03%, v/v) in sodium citrate buffer
(50 mM sodium citrate, pH 4.0). The absorbance at 405 nm was determined using a
SynergyTM 4 multi-mode microplate reader (BioTekH Instruments, Inc., Winooski,
VM). The binding curve y 5 xBMAX/(KD 1 x) was fitted to the saturation data in
Figure 2 | Characterization of inducible dimer- andmonomerization and
receptor binding affinity. (a) Inducible dimer- and monomerization of
the switch. VEGFSWITCH was incubated at room temperature without or
with coumermycin for 60 min, or with coumermycin for 30 min followed
by 30 min with novobiocin added. The resulting molecular weights were
determined using size exclusion chromatography. (b) Receptor-ligand
binding affinity. Saturation curve for the binding of the different
VEGFSWITCH variants to VEGFR2.
www.nature.com/scientificreports
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order to determine the relative maximum specific binding BMAX and the dissociation
constant KD of the VEGFSWITCH variants.
VEGFR2 phosphorylation and stimulation of DLL4 expression.Human umbilical
vein endothelial cells (HUVECs, Promocell, Heidelberg, Germany, cat. no. C-12200)
were cultivated in endothelial growth medium II (Lonza, Basel, Switzerland, cat. no.
C-22111). For VEGFR2 phosphorylation experiments, 150,000 cells were seeded in
1 ml of endothelial growth medium (Lonza, Basel, Switzerland, cat. no. C-22010) per
well of a 12-well plate and grown to confluence over 2 days. Subsequently, the cells
were starved in FCS-free endothelial growth medium containing 0.1% (w/v) BSA for
Figure 3 | VEGFSWITCH-ON bioactivity. (a) Comparison of VEGFR2 phosphorylation induced by VEGFSWITCH-ON, VEGF and VEGFGyrB with GyrB as a
negative control. HUVECs were stimulated for 15 min with the indicated protein concentrations after which whole-cell extracts were subjected to SDS-
PAGE followed by Western blot analysis using an antibody against phosphorylated VEGFR2 (P-VEGFR2 (Tyr 1175))18. Subsequently, the same
membrane was re-probed with an anti-VEGFR2 antibody18 for detection of the total levels of VEGFR2. (b) Stimulation of DLL4 expression. HUVECs
were stimulated for 4 days with the indicated VEGFSWITCH-ON concentrations after which whole-cell extracts were resolved by SDS-PAGE followed by
Western blot analysis. After transfer of the proteins to a PVDF-membrane, the membrane was cut into two pieces. The upper part of the membrane
(containing proteins with a molecular weight larger than 60 kDa) was probed with an anti-DLL4 antibody19. As a loading control, the levels of b-actin on
the lower part of the membrane (containing proteins with a molecular weight below 60 kDa) were detected using an anti-b-actin antibody20.
www.nature.com/scientificreports
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6 h. The cells were thereafter stimulated for 15 min with either 70 ng ml21 VEGF,
70 ng ml21 VEGFGyrB, 70 ng ml21 GyrB, or with 70 ng ml21, 280 ng ml21, 1120 ng
ml21 or 4480 ng ml21 VEGFSWITCH-ON. In all experiments the plates were covered
with an air-permeable filter (BREATseal, Greiner Bio-One, Frickenhausen, Germany,
cat. no. 676051) to ensure a homogenous oxygen supply. After stimulation, the
medium was discarded, the cells were washed with 1 ml ice-cold PBS and lysed in
90 ml ice-cold lysis buffer (Cell Signaling Technology, Danvers, MA, cat. no. 9803)
containing 1.0 mM phenyl-methylsulfonyl fluoride (Sigma-Aldrich, cat. no. P-7626)
for 5 min on ice. The cells were detached with a cell culture scraper and transferred to
an ice-cold eppendorf tube, after which theywere boiled in SDS loading buffer (2% (v/
v) glycerol, 10 mM Tris/HCl,4 g l21 SDS, 0.5 g l21 bromophenol blue, 2% (v/v) b -
mercaptoethanol, pH 6.8) for 5 min at 95uC. The proteins were separated by SDS-
PAGE (10% w/v) and phosphorylated VEGFR2 was detected via Western blotting
using an anti-phospho-VEGFR2 (Tyr1175) antibody (151000, Cell Signaling
Technology, cat. no. 2478) followed by incubation with an HRP-conjugated anti-
rabbit antibody. As a loading control, the total amount of VEGF2R was detected by
drying the polyvinylidene difluoride (PVDF) membrane, reactivating it in methanol,
and incubating it with an anti-VEGFR2 antibody (151000, Cell Signaling
Technology, cat. no. 2479) followed by an HRP-conjugated anti-rabbit antibody. In
all experiments the HRP was detected with Enhanced Chemiluminescent (ECL)
reagent (GE Healthcare, Chalfont UK, cat. no. RPN2232) and the images were
acquired using a LAS-4000 imager (Fujifilm, Du¨sseldorf, Germany).
For stimulation of DLL4 expression, 150,000 HUVECs were seeded in 1 ml of
endothelial growth medium per well of a 12-well plate and incubated for 4 days in the
absence, or in the presence of either 6 ng ml21, 12 ng ml21, 24 ng ml21 or 48 ng ml21
VEGFSWITCH-ON. After stimulation, the cells were lysed as described above and boiled
in SDS loading buffer for 5 min at 95uC.DLL4 expression was resolved by SDS-PAGE
(10%, w/v) followed by Western blot analysis. After transfer, the membrane was cut
into two pieces. The upper part of the membrane (containing proteins with a
molecular weight larger than 60 kDa) was probed with an anti-DLL4 antibody
(151000, Cell Signaling Technology, cat. no. 2589) followed by an HRP-conjugated
anti-rabbit antibody; whereas the lower part of the membrane (containing proteins
with a molecular weight below 60 kDa) was probed with an anti-b-actin antibody
(151000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, cat. no. sc-47778) followed
by an HRP-conjugated anti-mouse antibody (152500, Amersham Life Science,
Piscataway, NJ. cat. no. NA931).
Formation of endothelial microtissues. HUVECs were cultivated in endothelial
growth medium (Lonza, Basel, Switzerland, cat. no. CC-3162) supplemented with
10% (v/v) foetal calf serum (FCS, Gibco Life Technologies, Karlsruhe, Germany, cat.
no. 10500). For microtissue formation, 259000 cells ml21 were suspended in 0.2% (w/
v)methyl cellulose (Sigma-Aldrich, cat. no.M0512) inDMEM:EBM (4 parts DMEM/
F-12 1 GlutaMAXTM (Gibco Life Technologies, cat. no. 31331-028) and 1 part
endothelial basalmedium 2 (EBM-2, Lonza, cat. no. CC-3156) supplementedwith 1%
(v/v) penicillin/streptomycin solution (Gibco Life Technologies, cat. no. 15140-122)
and 10% (v/v) FCS). Droplets of 30 ml were placed in non-adhesive cell culture dishes
(Greiner Bio-One, Frickenhausen, Germany, cat. no. 633180) and cultured overnight
as hanging drops. The resulting spheroids were harvested in DMEM:EBM, washed
once with DMEM:EBM, and embedded into the hydrogels.
Hydrogel formation. PEG-based matrix metalloprotease-sensitive hydrogels were
synthesized as described previously17. In brief, stoichiometric amounts (final
concentration: 1.4% (w/v)) of 8-PEG-MMPsensitive-Lys and 8-PEG-Gln were mixed
with 50 mM Gln-RGD peptide, 400 spheroids ml21, and 10 U ml21 thrombin-
activated factor XIIIa in 50 mMTris-HCl (pH 7.6) supplemented with 50 mMCaCl2.
Droplets of 20 ml were placed between two siliconized glass slides (Sigmacote, Sigma-
Aldrich, cat. no. SL2) using 1-mm-thick spacers. In order to prevent spheroid
sedimentation, the glass slides were slowly rotated at room temperature until the
onset of gelation, and subsequently incubated for 30 min at 37uC. The hydrogels were
thereafter released and transferred into a 24-well plate. The final gels were incubated
for 15 h in 500 ml DMEM:EBMmedium at 37uC and 5% CO2 in the presence of 1 mg
VEGFSWITCH ml21 and either only DMSO, 25 ng ml21 coumermycin dissolved in
DMSO, or 25 ng ml21 coumermycin and 45 mg ml21 novobiocin.
Analytics. Z-stack phase contrast images (200 mm depth) were acquired at 10 3
magnification using a Zeiss Axiovert 200 M. HUVECs mobilization was quantified
by measuring the migration distance from the microtissue center. Cells with a
migration distance larger than 75 mm were considered in the statistical analysis. The
results were evaluated by a t-test, were p-values , 0.05 were considered to be
statistically significant.
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